Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Blood (2013) 122 (21): 2134.

https://doi.org/10.1182/blood.V122.21.2134.2134

Published: 2013

Journal Articles

OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS

Franco Locatelli, MD, Roberto Littera, MD, Daria Pagliara, MD, Benedetta Contoli, PhD, Giovanna Giorgiani, MD, Maria Ester Bernardo, MD, Angela Mastronuzzi, MD, Eugenia Piras, MD, Maria Grazia Orofino, MD, Claudio Giardini, MD, Carlo Carcassi, MD, Giorgio La Nasa, MD

Blood (2011) 118 (21): 149.

https://doi.org/10.1182/blood.V118.21.149.149

Published: 2011

Journal Articles

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Giuseppe Visani, MD, Lara Malerba, MD, Piero Galieni, MD, Claudio Giardini, MD, Sadia Falcioni, MD, Marco Rocchi, Alessandro Isidori, MD, PhD

Blood (2009) 114 (22): 4351.

https://doi.org/10.1182/blood.V114.22.4351.4351

Published: 2009

Journal Articles

Unrelated Donor Bone Marrow Transplantation for Class I-II Thalassemia Pediatric Patients.

Franco Locatelli, MD, Claudio Giardini, MD, Sebastian Giebel, MD, Franca Argiolu, MD, Andrea Pession, MD, Franca Fagioli, MD, Giovanna Giorgiani, MD, Giorgio La Nasa, MD

Blood (2005) 106 (11): 562.

https://doi.org/10.1182/blood.V106.11.562.562

Published: 2005

Journal Articles

Purified T Depleted Peripheral Blood and Bone Marrow CD34 Transplantation from Haploidentical Mother to Child with Thalassemia.

Pietro Sodani, MD, Marco Andreani, PhD, Paola Polchi, MD, Javid Gaziev, MD, Filippo Centis, PhD, Claudio Giardini, MD, Sonia Nesci, PhD, Silvia Cicconi, MD, Luca Spitaleri, MD, Flaminia Cassiani, MD, Guido Lucarelli, MD

Blood (2004) 104 (11): 5161.

https://doi.org/10.1182/blood.V104.11.5161.5161

Published: 2004

NARROW

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Unrelated Donor Bone Marrow Transplantation for Class I-II Thalassemia Pediatric Patients.

Purified T Depleted Peripheral Blood and Bone Marrow CD34 Transplantation from Haploidentical Mother to Child with Thalassemia.

Email alerts

ASH Publications

American Society of Hematology

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Unrelated Donor Bone Marrow Transplantation for Class I-II Thalassemia Pediatric Patients.

Purified T Depleted Peripheral Blood and Bone Marrow CD34 Transplantation from Haploidentical Mother to Child with Thalassemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only